Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
TNF Pharmaceuticals reports $2.50 loss per share for the quarter
TNF Pharmaceuticals on November 19, 2025 released results for the quarter ended September 30, 2025, reporting a loss per share of $2.50. In the year-ago quarter, a loss of -111,000 USD per share was reported. » More on finanzen.net
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -5.73m | 276.00% |
| EBITDA | -5.95m | 274.51% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €3.81m |
Number of shares | 2.37m |
52-week high/low | €56.75 - €1.55 |
| Dividends | No |
Beta | 2.69 |
P/E ratio | -0.20 |
PEG ratio | 0.00 |
P/B ratio | 0.36 |
P/S ratio | 0.00 |
Company profile
| Name | TNF Pharmaceuticals |
| CEO | Ian Rhodes CPA |
| Employees | 6 |
